BMY decide to stop enrollment in the late-stage study on Abecma due to growth in the newly diagnosed multiple myeloma treatment space.

Bristol Myers Squibb, 2seventy bio to discontinue enrollment in phase 3 KarMMa-9 study of Abecma in patients with newly diagnosed MM: Princeton, New Jersey Friday, September 27, 2 ...

This is a big approval for the company, given that Cobenfy doesn’t have the classic side effects seen in other antipsychotic ...

Despite being open for over a year across 18 countries, the trial managed to recruit only 10% of its target population.

The U.S. Food and Drug Administration (FDA) on Thursday approved Cobenfy (xanomeline and trospium chloride), developed by ...

Analyst Chris Shibutani from Goldman Sachs reiterated a Buy rating on Bristol-Myers Squibb (BMY – Research Report) and keeping the price ...

Wells Fargo analyst Mohit Bansal has maintained their neutral stance on BMY stock, giving a Hold rating on September 23. Mohit Bansal has ...

The event, reportedly attended by over 10,500 people, highlighted the talents of the musicians while emphasizing the importance of inclusion. Information ...

New York City Mayor Eric Adams has been charged with bribery and illegally soliciting a campaign contribution from a foreign national, according to a federal indictment unsealed on Thursday ...

In the Pact for the Future UN Member States pledged to do more to fight the climate crisis, a subject that has dominated several sessions at UN Headquarters this week.